That is necessary, because the method a protein in the body folds identifies if a pharmaceutical will have the ability to bind to that protein and be reliable. Simply put, we have to understand how these proteins fold if we desire a drug to work. Historically, this has been a trial-and-error procedure (second wave). Today, Alpha, Fold can anticipate protein folding with 92. 4% precision. That's going to make it a lot easier to create drugs that do what they're designed to do. This was an advancement almost nobody noticed. But it's going to have extensive implications for curing illness. I forecast that Alpha, Fold will be 98% precise by the end of 2021.
And, naturally, there will be a lot of financial investment opportunities in this area, too. Shifting topics It's going to be an excellent year for bitcoin. I'm bullish on it in 2021 (jeff brown). That stated, I still believe bitcoin will continue to be unstable. We're close to all-time highs. I would not be surprised if it drew back maybe significantly before going higher - tech predictions. I have actually been covering bitcoin for a long period of time now. One of the very first research reports I ever released was on bitcoin. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
However at the time of that initial suggestion, I titled my report "What's the Big Offer With Bitcoin?" That shows you where the discussion was at the time. We were primarily informing readers. However that's not the huge concern any longer. Now we're seeing institutional money lastly take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, specific niche enterprise. Mass, Mutual is a trusted 170-year-old organization. So consider that. In 5 years, we went from informing readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake.
And that's a big reason I'm bullish on it this year. genetic sequencing companies jeff brown. Regards, Jeff Brown, Editor, The Bleeding Edge I have a bonus prediction 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than 20 years. These business raised an overall of $172 billion. That's an all-time high beating the previous yearly record by 43%. I predict 2021 will be another record year in IPOs. There are so lots of terrific private companies on the edge of hitting the public markets And I have actually been dealing with a brand-new method for you to invest even before these companies go public.
This opportunity has actually been developing over the last few years. I can't wait to inform you everything about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Occasion to find out all the information. Go right here to schedule your spot totally free.
Emma Walsh here, managing editor of the Journal. Regular Journal readers know that tech isn't our normal beat (korean actress). And when it pertains to tech investing, we leave it to the professionals. The good news is, we have a number of such professionals in our Rolodex. Our coworker Jeff Brown will recognize to our long time readers. He is one of the most accomplished tech investing specialists we understand (the legacy report predictions). In truth, he had several triple-digit returns in his Brownstone Research portfolios last year. Here's what Jeff believes the tech sector will bring us in 2021 Each year, I like to take an appearance at the huge picture and forecast what's simply around the corner.
That includes things like 5G networks, biotech, synthetic intelligence, and far more. These patterns are experiencing rapid development and producing unbelievable chances for financiers. I wish to make sure all our readers are gotten ready for what's next. And with that in mind, let me draw the photo of what I see can be found in the next 12 months Our brand-new 5G (fifth-generation) cordless networks are a topic I've been covering for years now. brownstone research. However despite what many readers may think, this is a trend that's simply beginning. Although the COVID-19 pandemic disrupted supply chains in 2015, an impressive 250 million 5G-enabled gadgets were still offered.
And all of this ultimately caused Apple postponing the release of the 5G-enabled i, Phone 12 by 2 months (jeff brown biotech stocks). Losing 2 months of production and sales really affects the number of 5G devices are offered in the fiscal year. When you think about all of that, offering 250 million systems is amazing. More importantly, the delays brought on by the pandemic produced a load of pent-up need. Which need is now going to be pushed into 2021. In reality, I predict that more than 500 million 5G devices will be shipped in 2021 - black sea. And that's not my only 5G forecast When I've spoken about 5G in the past, I have actually explained its three various phases.
In Stage Two, 5G devices go on sale. 5G phones and other products start to reach customers. And in Stage 3, 5G services start to be provided (tech stock). That's when we begin to see applications running on 5G networks. Consider things like massive multiplayer video games over a cellphone. That's not possible with 4G. It will be with 5G. And my second 5G forecast for 2021 is that we will begin Stage 3 by this summertime. This begins something of a virtuous cycle: The majority of people don't truly care about the technology. However they will care if there are exciting applications that can only be accessed with a 5G phone.
That results in more 5G apps being developed. In truth, 5G is going to open up a suite of amazing applications: self-driving cars and trucks, the Internet of Things, robotic surgical treatment, and more. All of these innovations require 5G. The investment chances going forward will be huge. Stepping far from 5G, the next important technology I foresee in 2021 is CRISPR hereditary modifying. CRISPR represents "clustered frequently interspaced brief palindromic repeat." It's a mouthful. But it is among the most exciting advancements in biotechnology. At a high level, CRISPR is a technology that can edit our genetic makeup as if it were software.
The program can crash or not function properly. CRISPR utilizes a comparable idea but with our hereditary code. "Typos" in our genome can cause illness. CRISPR can correct these "typos." For years, CRISPR was mostly a niche technology that wasn't well understood. And throughout that time, there were truly only 3 business running in this space. However things are altering. CRISPR is no longer just theoretical. We're seeing real results. We're treating diseases and seeing that this technology simply works. And as a result, a "second crop" of early-stage CRISPR companies is going public and providing incredible returns. This whole industry is effectively a greenfield chance.
There's space for many business to exist in this area. diplomatic relations. And there will be more. That's my forecast for CRISPR in 2021. I predict that two or 3 more hereditary modifying companies will hold their IPOs. Sticking to biotechnology, we are seeing incredible things occurring at the merging of biotech and artificial intelligence (AI). Google's AI subsidiary, Deep, Mind, just revealed at the end of 2020 that its newest Alpha, Fold software can precisely anticipate the folding of a protein based exclusively on its amino acid sequence with 92. 4% accuracy. That is necessary due to the fact that the method a protein in the human body folds determines if a pharmaceutical will have the ability to bind to that protein and be effective.
Historically, this has actually been an experimental procedure. Today, Alpha, Fold can anticipate protein folding with 92. 4% accuracy. That's going to make it a lot easier to produce drugs that do what they're developed to do. And here's my next forecast. I forecast that Alpha, Fold will be 98% accurate by the end of 2021. And we will see not just one however several drug therapies produced using this innovation. This was among those developments that practically nobody noticed. However it's going to have profound ramifications for treating illness. And, naturally, there will be lots of financial investment opportunities in this area, too.
It's going to be a good year for bitcoin. I'm bullish on it in 2021. That said, I still believe bitcoin will continue to be unstable. We're close to all-time highs. I would not be surprised if it drew back perhaps substantially before going greater. I have actually been covering bitcoin for a long time now. Among the first research reports I ever released was on bitcoin - jeff brown biotech stocks. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on investment for anyone who followed my recommendation. However at the time of that initial suggestion, I titled my report, "What's the Big Offer With Bitcoin?" That reveals you where the discussion was at the time.
However nobody is asking that concern any longer. Now, we're seeing institutional money finally taking an interest in bitcoin. The big news was that Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some small, niche enterprise. melania trump. Mass, Mutual is a 150-year-old institution. So think about that. In five years, we went from educating readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. Which's a big factor why I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have one more bonus offer prediction In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown is worth about $27. 5 million and declares the details depends on date as of February 2021, however we might not individually verify this claim. Given Jeff Brown's past, he likely has a significant net worth, but we can't hammer down an exact figure at this minute. Brown is best understood for his sage-like ability to choose winning technology stocks. He invested more than 25 years looking into innovation business like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's comprehensive experience offers him an excellent viewpoint on the market. He's always on the hunt for new chances, and he shares much of his best choices in the Near Future Report.
That's high praise, however it's not absurdly reasoned. Brown has an excellent reputation as a stock-picker, and he successfully anticipated some of the biggest financial occasions of the past 20 years. Although he doesn't appear to release his choices to the public, the service's success is a direct sign of Brown's stock-picking expertise. Nobody on Wall Street gets it right every time, but Jeff Brown's precise predictions have actually earned him legions of devoted fans. That says a lot about his ability. The Near Future Report is published by Brownstone Research study, a popular financial research study publisher. Brownstone Research provides a number of research services with a variety of expertises - jeff bezos.
The business is likewise associated with Bonner & Partners, another well-respected research publisher - united arab emirates. On its site, Brownstone states its objective is to supply retail investors with professional-grade research study: "For too long, the finest financial investment research has not been readily available to individual financiers. It has actually been normally booked for financial investment banks, hedge funds, personal equity, and high-net-worth clients. jeff brown biotech genome sequencing. The mission of Brownstone Research study is to make that type of exclusive research study readily available to any investors looking to acquire an edge in the markets. The goal is basic to provide unique and successful financial investment research study discovered no place else." -Brownstone Research website excerpt from the Jeff Brown is the creator of Brownstone Research study, and he also serves as the firm's Chief Investment Expert.
With Brown assisting the ship, Brownstone Research study is a powerhouse publisher with lots to offer its clients. After decades of steady success at the helm of top-tier companies like Tesla and Area, X, Elon Musk is a family name throughout the majority of America. If you know even a little bit about the marketplace, you understand that he has a credibility as a King Midas of sorts. angel investor. Everything he touches relies on gold! Jeff is aware of Elon Musk's executive prowess, so he constantly has an eye out for the Silicon Valley rock star's next move. This time, Jeff has an early lead on Elon's next big job.
In truth, Brown thinks S.A.V. exponential tech investor. could be "the most significant trend of the 2020s, and he's not alone. Take a look at these quotes from other widely known S.A.V. bulls: Elon's next big act will be marrying 2 innovative innovations: artificial intelligence and electric automobiles. Musk hopes the mix will help him establish the very first fully-autonomous, self-driving cars ever. It's absolutely nothing except the automotive market's Holy Grail. As you understand, electrical lorries and self-driving automobile stocks have been big this year, however the Wall Street maker has actually approved hype without much tangible result. In spite of an extreme boost in competitors over the previous few years, Brown still believes Musk has the finest chance of putting it all together.
tech might be the magic string that connects everything together. S.A.V. represents Shared Autonomous Car, and it could be the future of transport. Basically, this innovation would enable you to rent your car as a self-governing, self-driving taxi when you're not using it. You just get out of the car and press a button on an app that informs the car to "sign up with the fleet." Next thing you understand, you're relaxing on your sofa while your cars and truck shuttles ride-sharers around town. Most importantly, you get to keep a large piece of the revenues. It sounds insane, but it could be closed than you think.